PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2026

  • ID: 4399906
  • Report
  • Region: Global
  • 404 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Amunix
  • Baxter
  • Bioverativ
  • Dimension Therapeutics
  • Opko Biologics
  • Sangamo Therapeutics
  • MORE
PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2026

Summary

Hemophilia A and B are rare, recessive, X-linked genetic disorders that almost exclusively afflict males and are characterized by the failure of blood to form normal clots after damage to veins and tissue. Hemophilia A is significantly more predominant than hemophilia B. According to the Centers for Disease Control and Prevention (CDC), there are approximately 20,000 patients in the US with hemophilia, and hemophilia A is four times more common than hemophilia B.

It is estimated that the total hemophilia A and B markets in the 7MM had a value of $6.68Bn in 2016. This analysis includes the sales of desmopressin (DDVAP), plasma-derived and recombinant factor concentrates, and alternative coagulation promoters (ACPs).

Hemophilia sales are forecast to grow to $7.97bn in 2026, at a modest Compound Annual Growth Rate (CAGR) of 1.8%. The US represents the largest market in hemophilia, accounting for approximately 60% of total product sales in 2016 and 2026. The five major European markets (5EU: France, Germany, Italy, Spain, and the UK) represents the second largest market region, accounting for approximately 32% of the total product sales in 2016 and 31% in 2026.

Major drivers of the hemophilia market in the 7MM over the forecast period include:
  • Increasing rates of routine prophylaxis in pediatric and adult hemophilia A and B.
  • The introduction and uptake of new long-acting factors and ACPs.
Traditionally, the hemophilia market has been dominated by short-acting rFVIII or FIX concentrates. However, in recent years the hemophilia market has become increasingly competitive due to the approval of extended half-life products that can reduce the burden associated with prophylaxis. These improvements have mainly benefited hemophilia B patients, while a substantial unmet need remains for hemophilia A patients and patients with inhibitors who do not respond to standard treatments.

The report "PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2026" provides overview of hemophilia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

In particular, this report provides the following:
  • Annualized hemophilia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in nine patient segments and two treatment strategies (episodic and prophylactic treatment), forecast from 2016 to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the hemophilia therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for hemophilia. The most promising candidate in Phase III development is profiled.
  • Analysis of the current and future market competition in the global hemophilia market. Insightful review of the key industry drivers, restraints and, challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Companies mentioned in this report: Amunix, Apitope, Aptevo Therapeutics, Bayer, Baxter, Baxalta, Biogen, BioMarin, Bioverativ, Catalyst Biosciences, Chugai, CSL Behring, Dimension Therapeutics, LFB, Novo Nordisk, Octapharma, Opko Biologics, Pfizer, Revo Biologics, Roche/Genentech, Sangamo Therapeutics, Shire, Spark Therapeutics, uniQure, Xenetic Biosciences.

Scope
  • Overview of hemophilia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized hemophilia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in nine patient segments and two treatment strategies (episodic and prophylactic treatment), forecast from 2016 to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the hemophilia therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for hemophilia. The most promising candidate in Phase III development is profiled.
  • Analysis of the current and future market competition in the global hemophilia market. Insightful review of the key industry drivers, restraints and, challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to:
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hemophilia market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amunix
  • Baxter
  • Bioverativ
  • Dimension Therapeutics
  • Opko Biologics
  • Sangamo Therapeutics
  • MORE
1 Table of Contents
2 Executive Summary
2.1 Sales for Hemophilia A and B Recombinant Therapies by Region, 2016-2026
2.2 Long-Acting rFVIIIs Have Not Lived Up to Expectations
2.3 Inhibitor Segment to Devalue Post-Alternative Coagulation Promoter Launch
2.4 Roche’s Emicizumab to Radically Impact Hemophilia A and Inhibitor Segments
2.5 Treatment Cost to Remain a Major Unmet Need
2.6 New Comers to Take Over Market Space From Established Companies
2.7 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification
4.3 Symptoms
4.3.1 Hemophilia A and B
4.3.2 Inhibitors
4.4 Prognosis and Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.4.3 Diagnosed Prevalent Cases
5.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
5.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitors
5.5 Epidemiological Forecast for Hemophilia A (2016-2026)
5.5.1 Diagnosed Prevalent Cases of Hemophilia A
5.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A
5.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A
5.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity
5.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors
5.6 Epidemiological Forecast for Hemophilia B (2016-2026)
5.6.1 Diagnosed Prevalent Cases of Hemophilia B
5.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B
5.6.3 Sex -Specific Diagnosed Prevalent Cases of Hemophilia B
5.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity
5.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors
5.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2016-2026)
5.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.7.3 Sex -Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
5.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
5.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
5.8 Discussion
5.8.1 Epidemiological Forecast Insight
5.8.2 Limitations of the Analysis
5.8.3 Strengths of the Analysis
6 Disease Management
6.1 Treatment Overview
6.1.1 Treatment Guidelines
6.1.2 Clinical Practice
6.2 US
6.2.1 Clinical Practice
6.3 France
6.3.1 Clinical Practice
6.4 Germany
6.4.1 Clinical Practice
6.5 Italy
6.5.1 Clinical Practice
6.6 Spain
6.6.1 Clinical Practice
6.7 UK
6.7.1 Clinical Practice
6.8 Japan
6.8.1 Clinical Practice
7 Competitive Assessment
7.1 Overview
7.2 Product Profiles - Hemophilia A
7.2.1 Short Acting rFVIII
7.2.2 Long Acting rFVIII
7.2.3 Plasma-Derived FVIII Concentrates
7.2.4 Desmopressin Acetate
7.3 Product Profiles - Hemophilia B
7.3.1 Short Acting rFIX
7.3.2 Long Acting FIX
7.3.3 Plasma-Derived FIX Concentrates
7.4 Product Profiles - Hemophilia A and B with Inhibitors
7.4.1 NovoSeven RT (Eptacog Alfa)
7.4.2 Feiba NF (Activated Prothrombin Complex Concentrate)
8 Unmet Needs and Opportunities
8.1 Overview
8.2 Reduction in Risk of Inhibitor Development in Previously Untreated Patients
8.2.1 Unmet Need
8.2.2 Gap Analysis
8.2.3 Opportunity
8.3 More Effective Treatments for Patients with Inhibitors
8.3.1 Unmet Need
8.3.2 Gap Analysis
8.3.3 Opportunity
8.4 Longer-Lasting Agents and More Convenient Administration Routes
8.4.1 Unmet Need
8.4.2 Gap Analysis
8.4.3 Opportunity
8.5 Treatments to Cure the Disease
8.5.1 Unmet Need
8.5.2 Gap Analysis
8.5.3 Opportunity
8.6 Decreasing the Costs Associated with Prophylaxis
8.6.1 Unmet Need
8.6.2 Gap Analysis
8.6.3 Opportunity
8.7 Individualized Prophylaxis
8.7.1 Unmet Need
8.7.2 Gap Analysis
8.7.3 Opportunity
9 Pipeline Assessment
9.1 Overview
9.2 Late-Stage Development Candidates - Hemophilia A
9.2.1 BAY 94-9027 (Damoctocog Alfa Pegol)
9.2.2 N8-GP (Turoctocog Alfa Pegol)
9.2.3 Emicizumab (ACE-910, RG-6013)
9.2.4 Fitusiran (ALN-AT3, SAR-439774)
9.3 Late-Stage Development Candidates - Hemophilia B
9.4 Late-Stage Development Candidates - Hemophilia A and B Patients with Inhibitors
9.4.1 LR-769 (rhFVIIa)
9.4.2 Obizur (Susoctocog Alfa)
9.4.3 CSL-689 (rVIIa-FP)
9.4.4 BAX-817 (rFVIIa BI)
9.5 Promising Approaches in Early-Stage Development
9.5.1 Alternative Coagulation Promoters - Tissue Factor Pathway Inhibitors
9.5.2 Gene Therapies
9.5.3 Replacement Strategies
9.5.4 Strategies to Prevent and Manage Inhibitors
9.5.5 Other Drugs in Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 Bayer
10.3.2 Bioverativ
10.3.3 CSL Behring
10.3.4 Novo Nordisk
10.3.5 Pfizer
10.3.6 Roche
10.3.7 Shire
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Market
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers - 5EU
11.3.4 Drivers and Barriers - France
11.3.5 Drivers and Barriers - Germany
11.3.6 Drivers and Barriers - Italy
11.3.7 Drivers and Barriers - Spain
11.3.8 Drivers and Barriers - UK
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.4 Forecasting Methodology
12.4.1 Diagnosed Hemophilia Patients
12.4.2 Percent Drug-Treated Patients
12.4.3 Drugs Included in Each Therapeutic Class
12.4.4 Launch and Patent Expiry Dates
12.4.5 General Pricing Assumptions
12.4.6 Individual Drug Assumptions
12.4.7 Pricing of Pipeline Agents
12.5 Primary Research - KOLs Interviewed for this Report
12.6 Primary Research - Prescriber Survey
12.7 Real-World Data
12.8 About the Authors
12.8.1 Analyst
12.8.2 Reviewer
12.8.3 Therapy Area Director
12.8.4 Epidemiologists
12.8.5 Reviewers
12.8.6 Global Director of Therapy Analysis and Epidemiology
12.8.7 Global Head and EVP of Healthcare Operations and Strategy
12.9 About
12.10 Contact
12.11 Disclaimer

List of Tables
Table 1: Hemophilia A and B: Key Metrics in the Seven Major Markets, 2016-2026
Table 2: Classification of Hemophilia A and B
Table 3: Symptoms of Hemophilia A and B
Table 4: Relationship of Bleeding Severity with Clotting Factor Level.
Table 5: Comorbidities for Hemophilia
Table 6: 7MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, Selected Years 2016-2026.
Table 7: 7MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016-2026.
Table 8: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016-2026.
Table 9: 7MM Treatment Guidelines for Hemophilia
Table 10: Most Prescribed Hemophilia A and B Drugs in the Global Markets, 2016
Table 11: Definition of Therapeutic Protocols in Hemophilia
Table 12: Country Profile - US, 2016
Table 13: Country Profile - France, 2016
Table 14: Country Profile - Germany, 2016
Table 15: Country Profile - Italy, 2016
Table 16: Country Profile - Spain, 2016
Table 17: Country Profile - UK, 2016
Table 18: Country Profile - Japan, 2016
Table 19: Leading Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2017
Table 20: Product Profile - Recombinate
Table 21: Summary of the Results of the Pivotal Trial of Recombinate
Table 22: Recombinate SWOT Analysis, 2017
Table 23: Product Profile - Kogenate FS
Table 24: Summary of the Results from the Trial that Led to the Approval of Kogenate FS
Table 25: Summary of the Results from the Trial that Studies Kogenate FS in Pediatric Prophylaxis
Table 26: Kogenate FS SWOT Analysis, 2017
Table 27: Product Profile -Helixate FS
Table 28: Helixate FS SWOT Analysis, 2017
Table 29: Product Profile - Advate
Table 30: Summary of the Results from the Part 2 Phase II/III Pivotal Trial of Advate
Table 31: Summary of the Results from the Phase IV Prophylaxis Study of Advate
Table 32: Advate SWOT Analysis, 2017
Table 33: Product Profile - Kovaltry
Table 34: Summary of the LEOPOLD I and II Trials of Kovaltry
Table 35: Summary of the LEOPOLD Kids Trial of Kovaltry
Table 36: Kovaltry SWOT Analysis, 2017
Table 37: Product Profile - Xyntha/ReFacto AF
Table 38: Summary of the Pivotal Trial of Xyntha
Table 39: Xyntha/ReFacto AF SWOT Analysis, 2017
Table 40: Product Profile - NovoEight
Table 41: Summary of the Results of The Guardian 1 Trial of NovoEight
Table 42: Summary of the Results of The Guardian 3 Trial of NovoEight
Table 43: NovoEight SWOT Analysis, 2017
Table 44: Product Profile - Nuwiq
Table 45: Summary of the Results from the GENA-01, GENA-08, and GENA-03 Trials of Nuwiq
Table 46: Nuwiq SWOT Analysis, 2017
Table 47: Product Profile - Eloctate
Table 48: Summary of the Results of the A-LONG Trial of Eloctate
Table 49: Eloctate SWOT Analysis, 2017
Table 50: Product Profile - Adynovate
Table 51: Summary of the Results of the PROLONG-ATE Trial of Adynovate
Table 52: Summary of the Results of the BAX855 Pediatric Trial of Adynovate
Table 53: Adynovate SWOT Analysis, 2017
Table 54: Product Profile - Afstyla
Table 55: Summary of the Results of the AFFINITY and Pediatric Trials of Afstyla
Table 56: Afstyla SWOT Analysis, 2017
Table 57: Marketed Plasma-Derived Replacement Therapies for Hemophilia A Patients, 2017
Table 58: Product Profile - BeneFIX
Table 59: Summary of the Results of the Phase III Trial of BeneFIX
Table 60: Summary of the Results that Proved the Effectiveness of BeneFIX as Prophylaxis Regimen
Table 61: Summary of the Results of the Phase III BeneFIX 1010 Study
Table 62: BeneFIX SWOT Analysis, 2017
Table 63: Product Profile - Rixubis
Table 64: Summary of the Results of the Pivotal Trial of Rixubis
Table 65: Summary of the Results of the Pediatric Trial of Rixubis
Table 66: Rixubis SWOT Analysis, 2017
Table 67: Product Profile - IXinity
Table 68: Summary of the Results of the Pivotal Trial of IXinity
Table 69: IXinity SWOT Analysis, 2017
Table 70: Product Profile - Alprolix
Table 71: Summary of the Results of the B-LONG Trial of Alprolix
Table 72: Summary of the Results of the Kids B-Long Trial of Alprolix
Table 73: Alprolix SWOT Analysis, 2017
Table 74: Product Profile - Idelvion
Table 75: Summary of the Results of the CSL654_3001 Trial of Idelvion
Table 76: Summary of the Results of the CSL654_3002 Trial of Idelvion
Table 77: Idelvion SWOT Analysis, 2017
Table 78: Product Profile - Rebynin
Table 79: Results of the Paradigm 2 Trial of Rebynin
Table 80: Results of the Pediatric Paradigm 5 Trial of Rebynin
Table 81: Rebynin SWOT Analysis, 2017
Table 82: Marketed Plasma-Derived Replacement Therapies for Hemophilia B Patients, 2017
Table 83: Product Profile - NovoSeven RT
Table 84: Summary of the Results of the Phase III Trial of NovoSeven
Table 85: NovoSeven RT SWOT Analysis, 2017
Table 86: Product Profile - Feiba NF
Table 87: Summary of the Results of the PROOF Trial of Feiba NF
Table 88: Feiba NF SWOT Analysis, 2017
Table 89: Unmet Needs and Opportunities in Hemophilia
Table 90: Product Profile - BAY 94-9027
Table 91: Efficacy of BAY 94-9027 in the PROTECT VIII study
Table 92: BAY 94-9027 SWOT Analysis, 2017
Table 93: Product Profile - N8-GP
Table 94: Efficacy of N8-GP in the Pathfinder 2 and 5Trials
Table 95: N8-GP SWOT Analysis, 2017
Table 96: Product Profile - Emicizumab
Table 97: Efficacy of Emicizumab in a Japanese Phase I/II Study
Table 98: Emicizumab SWOT Analysis, 2016
Table 99: Product Profile - Fitusiran
Table 100 : Efficacy of Fitusiran in the Part-D Phase I Study
Table 101: Fitusiran SWOT Analysis, 2017
Table 102: Product Profile - LR-769
Table 103: LR-769 SWOT Analysis, 2017
Table 104: Product Profile - Obizur
Table 105: Obizur SWOT Analysis, 2017
Table 106: Product Profile - CSL-689
Table 107: CSL-689 SWOT Analysis, 2017
Table 108: Product Profile - BAX-817
Table 109: BAX-817 SWOT Analysis, 2017
Table 110: TFPI inhibitors - Early-Stage Pipeline, 2017
Table 111: Hemophilia A and B Gene Therapies - Early-Stage Pipeline, 2017
Table 112: Hemophilia A and B Recombinant Replacement Therapies - Early-Stage Pipeline, 2017
Table 113: Drugs in Development for Hemophilia, 2016
Table 114: Key Companies in the Hemophilia A and B Recombinant Therapies Market, 2016-2026
Table 115: Bayer’s Hemophilia Portfolio Assessment, 2015
Table 116: Bayer SWOT Analysis, 2017
Table 117: Bioverativ/Sobi’s Hemophilia Portfolio Assessment, 2017
Table 118: Bioverativ SWOT Analysis, 2017
Table 119: CSL Behring’s Hemophilia Recombinant Portfolio Assessment, 2017
Table 120: CSL Behring SWOT Analysis, 2017
Table 121: Novo Nordisk’s Hemophilia Recombinant Portfolio Assessment, 2017
Table 122: Novo Nordisk SWOT Analysis, 2017
Table 123: Pfizer’s Hemophilia Recombinant Portfolio Assessment, 2017
Table 124: Pfizer SWOT Analysis, 2017
Table 125: Roche’s Hemophilia Recombinant Portfolio Assessment, 2017
Table 126: Roche SWOT Analysis, 2017
Table 127: Shire’s Hemophilia Recombinant Portfolio Assessment, 2017
Table 128: Shire SWOT Analysis, 2017
Table 129: Global Hemophilia A and B Market - Drivers and Barriers, 2016-2026
Table 130: Key Events Impacting Sales for Hemophilia A and B in the US, 2016-2026
Table 131: US Hemophilia A and B Market - Drivers and Barriers, 2016-2026
Table 132: Key Events Impacting Sales for Hemophilia A and B Therapeutics in the 5EU, 2016-2026
Table 133: 5EU Hemophilia A and B Market - Drivers and Barriers, 2016-2026
Table 134: French Hemophilia A and B Market - Drivers and Barriers, 2016-2026
Table 135: German Hemophilia A and B Market - Drivers and Barriers, 2016-2026
Table 136: Italian Hemophilia A and B Market - Drivers and Barriers, 2016-2026
Table 137: Spanish Hemophilia A and B Market - Drivers and Barriers, 2016-2026
Table 138: UK Hemophilia A and B Market - Drivers and Barriers, 2016-2026
Table 139: Key Events Impacting Sales for Hemophilia A and B in Japan, 2016-2026
Table 140: Japanese Hemophilia A and B Market - Drivers and Barriers, 2016-2026
Table 141: Key Launch Dates
Table 142: Key Historical and Projected Patent Expiry Dates
Table 143: Average Body Weight Across the 7MM
Table 144: Average Cost of Therapy of Plasma-Derived FVIII Concentrates in the 7MM
Table 145: Average Cost of Therapy of Recombinate in the 7MM
Table 146: Average Cost of Therapy of Kogenate FS in the 7MM
Table 147: Average Cost of Therapy of Helixate FS in the 7MM
Table 148: Average Cost of Therapy of Advate in the 7MM
Table 149: Average Cost of Therapy of Kovaltry in the 7MM
Table 150: Average Cost of Therapy of Xyntha in the 7MM
Table 151: Average Cost of Therapy of NovoEight in the 7MM
Table 152: Average Cost of Therapy of Nuwiq in the 7MM
Table 153: Average Cost of Therapy of Eloctate in the 7MM
Table 154: Average Cost of Therapy of Adynovate in the 7MM
Table 155: Average Cost of Therapy of Afstyla in the 7MM
Table 156: Average Cost of Therapy of Plasma-derived FIX Concentrates in the 7MM
Table 157: Average Cost of Therapy of BeneFIX in the 7MM
Table 158: Average Cost of Therapy of Rixubis in the 7MM
Table 159: Average Cost of Therapy of IXinity in the 7MM
Table 160: Average Cost of Therapy of Alprolix in the 7MM
Table 161: Average Cost of Therapy of Idelvion in the 7MM
Table 162: Average Cost of Therapy of NovoSeven in the 7MM
Table 163: Average Cost of Therapy of Feiba in the 7MM
Table 164: Average Cost of Therapy of DDAVP in the 7MM
Table 165: Physicians Surveyed

List of Figures
Figure 1: Sales for Hemophilia A and B Therapeutics by Drug Class, 2016-2026
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents, 2016-2026
Figure 3: Key Company Portfolio Positioning in Hemophilia A and B, 2016-2026
Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia A (Cases per 100,000 Population), All Ages, 2016
Figure 5: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia B (Cases per 100,000 Population), All Ages, 2016
Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
Figure 7: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
Figure 8: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
Figure 9: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016
Figure 10: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016
Figure 11: 7MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, Both Sexes, All Ages, N, 2016
Figure 12: 7MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, Both Sexes, All Ages, N, 2016
Figure 13: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, 2016
Figure 14: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2016
Figure 15: 7MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, Both Sexes, All Ages, N, 2016
Figure 16: 7MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016
Figure 17: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2016
Figure 18: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, All Ages, N, 2016
Figure 19: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, Both Sexes, All Ages, N, 2016
Figure 20: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016
Figure 21: Treatment Flowchart for Severe Patients with Inhibitors
Figure 22: Competitive Assessment of Late-Stage Pipeline Agents, 2016-2026
Figure 23: Overview of the Development Pipeline in Hemophilia, 2016-2026
Figure 24: Hemophilia A - Phase III Pipeline, 2017
Figure 25: BAY94-9027’s Clinical Development in Hemophilia A
Figure 26: Clinical and Commercial Positioning of BAY94-9027
Figure 27: N8-GP’s Clinical Development in Hemophilia A
Figure 28: Clinical and Commercial Positioning of N8-GP
Figure 29: Emicizumab’s Clinical Development in Hemophilia A
Figure 30: Clinical and Commercial Positioning of Emicizumab
Figure 31: Clinical and Commercial Positioning of Fitusiran
Figure 32: Hemophilia A and B with Inhibitors - Phase III Pipeline, 2017
Figure 33: LR-769’s Clinical Development in Patients with Inhibitors
Figure 34: Clinical and Commercial Positioning of LR-769
Figure 35: Obizur’s Clinical Development in Patients with Inhibitors
Figure 36: Clinical and Commercial Positioning of Obizur
Figure 37: CSL-689’s Clinical Development in Patients with Inhibitors
Figure 38: Clinical and Commercial Positioning of CSL-689
Figure 39: Clinical and Commercial Positioning of BAX-817
Figure 40: Company Portfolio Analysis in Hemophilia A and B, 2016-2026
Figure 41: Global Sales of Hemophilia Therapeutics by Company, 2016-2026
Figure 42: Global Sales for Hemophilia A and B by Drug Class, 2016-2026
Figure 43: Global Sales for Hemophilia A and B Therapeutics by Region, 2016-2026
Figure 44: Sales for Hemophilia A and B Therapeutics in the US by Drug Class, 2016-2026
Figure 45: Sales for Hemophilia A and B Therapeutics in the 5EU by Drug Class, 2016-2026
Figure 46: Sales for Hemophilia A and B Therapeutics in the 5EU by Country, 2016-2026
Figure 47: Sales for Hemophilia A and B Therapeutics in Japan by Drug Class, 2016-2026
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Amunix
  • Apitope
  • Aptevo Therapeutics
  • Bayer
  • Baxter
  • Baxalta
  • Biogen
  • BioMarin
  • Bioverativ
  • Catalyst Biosciences
  • Chugai
  • CSL Behring
  • Dimension Therapeutics
  • LFB
  • Novo Nordisk
  • Octapharma
  • Opko Biologics
  • Pfizer
  • Revo Biologics
  • Roche/Genentech
  • Sangamo Therapeutics
  • Shire
  • Spark Therapeutics
  • uniQure
  • Xenetic Biosciences
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll